All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubLymphoma HubMDS HubMPN HubMultiple Myeloma

How do pre-allo-HSCT conditioning regimens impact GvHD outcomes in myelofibrosis patients?

During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Guru Subramanian Guru Murthy, Medical College of Wisconsin, Milwaukee, US. We asked, how do pre-allo-HSCT conditioning regimens impact GvHD outcomes in myelofibrosis patients?

How do pre-allo-HSCT conditioning regimens impact GvHD outcomes in myelofibrosis patients?

In this video, Murthy discusses the factors that can be modified before transplant, including conditioning intensity and conditioning regimens. He also discusses the findings of his teams' study, which was conducted using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, and included adults aged ≥18 years with the diagnosis of myelofibrosis who underwent allo-HSCT between 2009–2019. Lastly, he comments on the role of pre-transplant ruxolitinib.

 

Share: